Senses Disorder TRIZ Cases

A trophic composition with a complex nutritive base and collagenase inhibitor promotes corneal epithelial cell viability.

Acetate buffers at pH 4.5-5.5 prevent aggregation of TACI-immunoglobulin fusion proteins during storage.

Aceclidine eye drops activate M1 receptors to constrict the pupil, improving near vision without ciliary muscle spasms.

Novel pyrazolo[3,4-b]pyridine compounds inhibit xanthine oxidase to reduce severe side effects from allopurinol.

Imatinib eye drops inhibit tyrosine kinase activity to prevent corneal damage and inflammation in dry eye syndrome.

Exosomes from mesenchymal stem cells deliver HSP70 protein to shield auditory hair cells from ototoxic drug damage.

Phase-separated multi-block copolymers prevent protein aggregation and acidic micro-environments by creating hydrophilic pathways for sustained release.

Pyridopyrazinone derivatives restore glucose-responsive insulin release, preventing hyperinsulinemia and beta cell exhaustion in type 2 diabetes treatment.

A dynamic dosing regimen using VEGF antagonists adjusts treatment intervals to maintain therapeutic efficacy.

Topical amarogentin activates bitter taste receptors to reduce inflammation and strengthen skin barrier function.

Guide RNA targets single nucleotide polymorphism in mutant allele to enable precise CRISPR-mediated mRNA degradation.

Peptide-based proteasome inhibitors with C-terminal electrophilic groups inactivate target enzymes via covalent bonding.

Formula I compounds bypass reduced nitric oxide bioavailability by directly activating heme-dependent soluble guanylate cyclase to treat pulmonary hypertension.

Selective Bcl-2 inhibitors minimize off-target effects on Bcl-xL while treating systemic lupus erythematosus, lupus nephritis, and Sjogren's Syndrome.

Isolate retinal progenitor cells from mixed cultures using phase-bright golden neurosphere morphology without genetic markers.

Alcoholic alkali hydrolysis isolates lutein and zeaxanthin crystals, resolving stability trade-offs caused by harsh solvents.

Segmented bicyclic peptides resist rapid plasma degradation while maintaining sub-nanomolar binding specificity for human kallikrein.

Targeted FPR2 agonists activate local receptors in the eye, reducing side effects like elevated IOP while accelerating corneal wound healing.

Polyphenol enrichment via ultracentrifugation yields fractions that eradicate resistant bacteria and synergize with antibiotics.

Engineered Fc-region variants with specific amino acid mutations enable selective binding to Staphylococcal protein A.

A trans-2-decenoic acid derivative activates the MAP kinase pathway to provide neuroprotective effects.

Nasal betahistine treats secondary Meniere's disease by improving Eustachian tube function and inner ear oxygenation without exacerbating dysfunction.

Small synthetic molecules replace complex natural proteins to activate FGFRs, resolving manufacturing difficulties while maintaining therapeutic efficacy.

Anti-BMP4 VHH antibodies bind a conformational epitope within the BMPR1a binding site to block signaling pathways.

A non-retinoid compound modulates the visual cycle to normalize electroretinogram responses and enhance retinal neuronal cell survival.

Converting pyrimidine nucleoside 5'-triphosphate into a cyclic intermediate at room temperature increases synthesis yield to over 50% while reducing by-product formation.

Glutamate-based buffers in AM-14 formulations reduce subcutaneous injection pain while maintaining stability at 60-250 mg/ml.

Nitroderivatives modify molecular structures to boost endothelin receptor antagonism.

Segmenting polyethylene glycol chains reduces blood-brain barrier permeability while preserving in vitro activity.

Medium-chain triglycerides and buffering agents stabilize low-concentration PVP-I solutions, preventing free iodine loss for effective antimicrobial activity.

A monoclonal antibody binds human plasmalemma vesicle-associated protein to block vascular fenestrae formation.

Hydrolysis and decarboxylation of chlorogenic acids yield phenolic compounds that reduce amyloid fibril formation in brain tissue.

Modified anti-human CD3 antibodies reduce effector function to minimize cytokine release syndrome while treating autoimmune disorders.

Single-dose rAAV2 vectors expressing aflibercept resolve compliance issues from frequent injections while maintaining disease control.

Benzimidazole sulfonamides target the p110α isoform to reduce off-target effects while maintaining potent anticancer efficacy.

Targeting APOE-driven IL-6 expression resolves therapeutic gaps in atrophic age-related macular degeneration by suppressing subretinal inflammation.

M6P antibody conjugates target the CI-M6PR receptor to internalize and degrade extracellular antigens.

Segmenting the complement system via MASP-2 inhibition preserves classical pathway immune complex handling while blocking lectin-mediated tissue injury.

Hyaluronic acid stabilizes a multiphase ophthalmic composition, eliminating emulsifiers that cause allergic reactions and irritation.

Enzymatic activation of precursors via lactone formation releases hydrogen sulfide without consuming free thiols.

Complementary residue sets at the CH1-CL interface favor heterodimer formation over homodimers, resolving yield and purity bottlenecks in manufacturing.

A lateral flow assay detects iC3b and intact C3 levels using specific non-cross-reactive antibodies.

A pharmaceutical composition combining coenzyme Q10 and vitamin A treats vocal cord and olfactory disorders through synergistic tissue protection.

A method isolating mesenchymal-like stem cells using a cell-permeable three-dimensional culture unit to select cystic embryoid bodies.

Organic molecules inhibit Syk protein binding to natural partners by targeting specific epitopes outside the catalytic domain.

Combining SSTR2 and SSTR5 targeting somatostatin analogs maintains hormone secretion inhibition while minimizing hyperglycemic side effects.

Formula (I) compounds modulate the integrated stress response pathway by optimizing pharmacokinetic properties to treat associated diseases.

Direct plasminogen administration dissolves fresh and old thrombi while avoiding the systemic bleeding caused by conventional activators.